Diabetes drug shows promise for kidney protection in new study

NCT ID NCT06291155

Recruiting now Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how an FDA-approved diabetes drug, Canagliflozin (Invokana), might protect the kidneys in people with type 2 diabetes. Twenty adults aged 18-80 with type 2 diabetes for at least 3 years will take the drug daily for 6 months. Researchers will use kidney biopsies and MRIs to see if the drug helps prevent kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Canagliflozin (Invokana), an SGLT2 inhibitor drug
What this could lead to: If successful, this could reveal exactly how SGLT2 inhibitors protect the kidneys in type 2 diabetes, potentially leading to better treatments.
What could go wrong: This is a very small, early-phase study with only 20 participants, so results may not apply to everyone. The study involves invasive kidney biopsies, which carry some risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE TYPE 2 DIABETES

Contacts and locations

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.